MOLN Molecular Partners AG
$4.20▲ +0.00%
Healthcare
Other
Volume 61
Avg Volume (10D) 650
Key Metrics & Fundamentals
Market Cap
$160.88M
P/E Ratio
–
Div Yield
–%
52W Range
3.53 - 5.36
% vs 50 MA
0.82%
% vs 200 MA
-1.46%
RSI-14
46.3
MACD Histogram
-0.0300
Beta (1Y vs SPY)
0.36
Free Cash Flow
-$10.81M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$13.07M
COGS
–
Operating Exp
$13.59M
Operating Income
-$13.59M
EBIT
-$13.59M
Pretax Income
-$13.56M
Net Income
-$13.56M
EPS (Diluted)
-0.35
Price & Volume History
Loading chart…
Recent News
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
GlobeNewswire · Aug 25, 2026 5:00 AM
Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy
MT Newswires · Jul 16, 2026 7:34 AM
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
GlobeNewswire · Jul 16, 2026 5:00 AM
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
GlobeNewswire · Jul 15, 2026 5:00 AM
Molecular Partners Makes Progress on Radiotherapy Cancer Candidates
MT Newswires · Jul 6, 2026 9:51 AM
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
GlobeNewswire · Jul 6, 2026 5:00 AM
Molecular Partners Doses First Patients in Lung Cancer Trial
MT Newswires · Jul 2, 2026 7:46 AM
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
GlobeNewswire · Jul 2, 2026 5:00 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See MOLN's money flow as a full page
Social Sentiment
No Reddit posts found for MOLN.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.